NIMG-22. HIGH-GRADE GLIOMA OUTCOMES IN THE PHASE 1 BXQ-350 TRIAL OF CANCER-SELECTIVE SapC-DOPS NANOVESICLES

ABSTRACT: Abstract

BACKGROUND

Saposin C-dioleylphosphatidylserine (SapC-DOPS) is a novel blood-brain barrier penetrant nanoliposomal agent that targets externalized phosphatidylserine overexpressed on tumor cell membranes. A recent Phase 1a BXQ-350 trial (NCT02859857) reported SapC-DOPS was well tolerated in both solid tumor and high-grade glioma (HGG) patients with potential for treating clinically challenging gliomas, including their diffuse infiltrative components.

METHODS

We evaluated the HGG subset of the ongoing Phase 1 study of IV BXQ-350 administered on Days 1–5, 8, 10, 12, 15, 22 (cycle 1) and each 28 day cycles thereafter. MRI neuroimaging (e.g. Axial T1-post-contrast Ax SE T1 POST-FC and medically necessary views) at Days 29, 57, 113, and 171 (or withdrawal) were complet

SUBMITTER: Puduvalli V 

PROVIDER: S-EPMC6217345 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature